GlyProVac

Odense, Denmark

GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).

$467K raised

Feb 2024

Grant

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has GlyProVac raised?

GlyProVac has raised $467K in total funding. The most recent round was Grant. The last funding was announced in February 2024.

Who are GlyProVac's investors?

GlyProVac's investors include CARB-X.

Where is GlyProVac headquartered?

GlyProVac is headquartered in Odense, Denmark.

What does GlyProVac do?

GlyProVac is pursuing the development of a glycoprotein based vaccine against Enterotoxigenic Escherichia coli (ETEC).

What stage is GlyProVac at?

GlyProVac is at the Grant stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated February 29, 2024.

MLA

"GlyProVac — Funding & Investors." VCBacked, February 29, 2024, https://www.vcbacked.co/company/glyprovac. Accessed July 2, 2026.

APA

VCBacked. (2024). GlyProVac — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/glyprovac

Wikipedia (cite web)

{{cite web |title=GlyProVac — Funding & Investors |url=https://www.vcbacked.co/company/glyprovac |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated February 29, 2024.